
|Articles|March 9, 2010
- December 2009
- Volume 0
Amgen Honored for Best Pipeline & Best New Drug
Author(s)Onclive Team
Advertisement
Articles in this issue
almost 16 years ago
Do Insurers Spend Too Much on Administration and Too Little on Care?almost 16 years ago
The Effect of New Treatments on Cancer-related Bone Lossalmost 16 years ago
Exercise Maintains Function, Improves QoL for Patients With Lymphomaalmost 16 years ago
Continuing Education Opportunities on the Webalmost 16 years ago
News Briefs & FDA Updatesalmost 16 years ago
News & Opinionalmost 16 years ago
Decline in Cancer Deaths No Reason to Get ComplacentAdvertisement
Latest CME
Advertisement
Advertisement
Trending on OncLive
1
Long-Term Cilta-Cel Data Show Low Rates of PFS Events in Standard-Risk R/R Myeloma
2
FDA Updates Axi-Cel Label to Remove Limitation of Use in R/R PCNSL
3
Real-World Data Support Clinical Benefit With Lifileucel in Previously Treated Advanced Melanoma
4
Nonresponse to Bridging Therapy and Peak ALC After Cilta-Cel Are Associated With Neurotoxicity, NRM in Myeloma
5




































